Stay updated with breaking news from Bryan clifton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
(1) Acquisition of Kalypso accelerates the clinical development of psychedelic infusion therapies ELE-Ket+ and ELE-Psilo+ are psychedelic infusion therapies in clinical development for adjunctive treatment of major depressive disorder; initiation of Phase 2 clinical trials expected in Q4 2021 Eleusis Ltd, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the launch of its clinical development of psychedelic infusion therapies and acquisition of Kalypso Wellness Centers ( Kalypso ), a leading provider of ketamine infusion therapies in the United States. Under the terms of the agreement, Eleusis will acquire Kalypso and its intellectual property in an all-stock transaction. ....